Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorVeillon, Remi
dc.contributor.authorSakai, Hiroshi
dc.contributor.authorLe, Xiuning
dc.contributor.authorFelip Font, Enriqueta
dc.contributor.authorCortot, Alexis
dc.contributor.authorSmit, Egbert
dc.date.accessioned2022-09-09T07:16:34Z
dc.date.available2022-09-09T07:16:34Z
dc.date.issued2022-06
dc.identifier.citationVeillon R, Sakai H, Le X, Felip E, Cortot AB, Smit EF, et al. Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management. Clin Lung Cancer. 2022 Jun;23(4):320–32.
dc.identifier.issn1525-7304
dc.identifier.urihttp://hdl.handle.net/11351/8083
dc.descriptionEdema; Nausea; Non-small cell lung cancer
dc.description.abstractIntroduction The MET inhibitor tepotinib demonstrated durable clinical activity in patients with advanced MET exon 14 (METex14) skipping NSCLC. We report detailed analyses of adverse events of clinical interest (AECIs) in VISION, including edema, a class effect of MET inhibitors. Patients and Methods Incidence, management, and time to first onset/resolution were analyzed for all-cause AECIs, according to composite categories (edema, hypoalbuminemia, creatinine increase, and ALT/AST increase) or individual preferred terms (pleural effusion, nausea, diarrhea, and vomiting), for patients with METex14 skipping NSCLC in the phase II VISION trial. Results Of 255 patients analyzed (median age: 72 years), edema, the most common AECI, was reported in 69.8% (grade 3, 9.4%; grade 4, 0%). Median time to first edema onset was 7.9 weeks (range: 0.1-58.3). Edema was manageable with supportive measures, dose reduction (18.8%), and/or treatment interruption (23.1%), and rarely prompted discontinuation (4.3%). Other AECIs were also manageable and predominantly mild/moderate: hypoalbuminemia, 23.9% (grade 3, 5.5%); pleural effusion, 13.3% (grade ≥ 3, 5.1%); creatinine increase, 25.9% (grade 3, 0.4%); nausea, 26.7% (grade 3, 0.8%), diarrhea, 26.3% (grade 3, 0.4%), vomiting 12.9% (grade 3, 1.2%), and ALT/AST increase, 12.2% (grade ≥ 3, 3.1%). GI AEs typically occurred early and resolved in the first weeks. Conclusion Tepotinib was well tolerated in the largest trial of a MET inhibitor in METex14 skipping NSCLC. The most frequent AEs were largely mild/moderate and manageable with supportive measures and/or dose reduction/interruption, and caused few withdrawals in this elderly population.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesClinical Lung Cancer;23(4)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectPulmons - Càncer - Tractament
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.mesh/drug therapy
dc.subject.meshTreatment Outcome
dc.titleSafety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.cllc.2022.03.002
dc.subject.decscarcinoma de pulmón de células no pequeñas
dc.subject.decs/farmacoterapia
dc.subject.decsresultado del tratamiento
dc.relation.publishversionhttps://doi.org/10.1016/j.cllc.2022.03.002
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Veillon R] CHU Bordeaux, Service des Maladies Respiratoires, Bordeaux, France. [Sakai H] Department of Thoracic Oncology, Saitama Cancer Center, Saitama, Japan. [Le X] Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. [Felip E] Department of Oncology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Cortot AB] Univ. Lille, CHU Lille, CNRS, Inserm, Institut Pasteur de Lille, UMR9020 – UMR-S 1277 - Canther, Lille, France. [Smit EF] Netherlands Cancer Institute, Amsterdam, The Netherlands
dc.identifier.pmid35466070
dc.identifier.wos000810868000011
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record